Status:

COMPLETED

Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

Lead Sponsor:

National Center for Complementary and Integrative Health (NCCIH)

Conditions:

Epilepsy

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine if Omega-3 fatty acids reduce seizures and modify cardiac risk factors in people with epilepsy.

Detailed Description

Epilepsy is a common and disabling condition, characterized by recurrent seizures. Sudden unexpected death (SUDEP) is a major cause of mortality in people with epilepsy. SUDEP accounts for up to 20% o...

Eligibility Criteria

Inclusion

  • Male or female, age 18 - 70
  • History of intractable localization related/partial onset seizures and generalized tonic/clonic or tonic seizures defined according to International League Against Epilepsy (ILAE) classification as:
  • A history compatible with localization related partial epilepsy
  • A history of generalized tonic clonic or tonic seizures with loss of consciousness
  • Three or more simple partial, complex partial or tonic-clonic seizures per month
  • An EEG and/or an MRI consistent with a localization related epilepsy
  • Evidence of at least three seizures per month for at least two months prior to the study
  • Exposure to at least one antiepileptic drug at adequate dose

Exclusion

  • Significant or progressive medical, cardiac, or other illness
  • Allergy to fish products or fish oil
  • History of a coagulation disorder
  • History of non-epileptic seizures
  • Consumption of Fish Oil at any time 30 days or less prior to enrollment
  • Any change in antiepileptic drugs for 30 days or less prior to enrollment
  • Treatment with Warfarin for 30 days or less prior to enrollment
  • Previous poor compliance with therapy
  • Drug or alcohol abuse
  • Uncountable seizures as a result of seizure clustering, or inadequate supervision if the patient cannot count their own seizures.
  • Pregnancy

Key Trial Info

Start Date :

May 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2011

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00871377

Start Date

May 1 2008

End Date

August 1 2011

Last Update

February 7 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UCLA General Clinical Research Center

Los Angeles, California, United States, 90095